Diabetic Nephropathy & Hypertension

Diabetic nephrosis is characterized by cardiovascular disease, progressive proteinuria, glomerulosclerosis, and decline in capillary vessel filtration rate (GFR) resulting in ESRD. Cardiovascular disease within the setting of polygenic disease is outlined as a pulse force per unit area force per unit area mmHg or a pulsation force per unit area force per unit area mmHg. associate elevated urinary simple protein excretion rate, exaggerated force per unit area (BP), and a continuous loss of excretory organ operate are characteristics of DN. Screening for small proteinuria is central to polygenic disease care, and antihypertensive drug agents are used for the first interference and treatment of DN. Angiotensin-converting accelerator inhibitors and angiotnin receptor blockers play central roles and have protecting properties on the far side their BP-lowering effects. BP management in relevancy DN is that the main focus of this review, however tight management of the aldohexose level is equally vital.

  • Hypertension Management
  • Pathogenesis of diabetic nephropathy
  • Hypertension-Clinical and Experimental Models
  • Diabetic Nephropathy–Biomarkers of Disease

Related Conference of Diabetic Nephropathy & Hypertension

September 20-21, 2023

8th World Kidney Congress

Paris, France
October 25-26, 2023

11th World Congress on Epidemiology & Public Health

Nova Scotia, Canada
November 15-16, 2023

27th European Nephrology Conference

Barcelona, Spain
November 20-21, 2023

22nd Annual Conference on Urology and Nephrological Disorders

Amsterdam, Netherlands
February 22-23, 2024

20th World Nephrology Conference

Zurich, Switzerland

Diabetic Nephropathy & Hypertension Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in